Nielsen Kirk G.'s Form 4/A amendment
AmendedSpyGlass Pharma, Inc. (SGP) · filed Feb 11, 2026
- Accession no.
- 0001193125-26-046833
- Filed
- Feb 11, 2026
- Trade date
- Feb 9, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Feb 10, 2026
This filing lists 4 derivative transactions. It carries over 5 transactions from the original filing that it did not restate. Open-market purchases total $2.64M. It was filed 2 days after the trade.
This amendment restates part of 0001193125-26-045029 (filed Feb 10, 2026). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nielsen Kirk G.CIK 0001523522 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | Common Stock | CConversionDisposed | −1,690,230 | –F1 | – | 0 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | CConversionDisposed | −548,067 | –F1 | – | 0 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | CConversionDisposed | −548,067 | –F1 | – | 0 | Indirect | Duplicate filing |
| Feb 9, 2026 | Common Stock | CConversionDisposed | −359,255 | –F1 | – | 0 | Indirect | Duplicate filing |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001193125-26-045029 (filed Feb 10, 2026).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | Common Stock | CConversionAcquired | +1,690,230 | –F1 | – | 1,690,230 | Indirect | |
| Feb 9, 2026 | Common Stock | CConversionAcquired | +548,067 | –F1 | – | 2,238,297 | Indirect | |
| Feb 9, 2026 | Common Stock | CConversionAcquired | +548,067 | –F1 | – | 2,786,364 | Indirect | |
| Feb 9, 2026 | Common Stock | CConversionAcquired | +359,255 | –F1 | – | 3,145,619 | Indirect | |
| Feb 9, 2026 | Common Stock | PPurchaseAcquired | +165,000 | $16.00 | +$2,640,000 | 3,310,619 | Indirect |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F1
Each of the Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock automatically converted into shares of Common Stock on a one-for-5.7329 basis without payment of further consideration immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
Referenced by the price of 4 transactions in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration and such preferred stock had no expiration date.
Referenced by the price of 4 transactions in Table II.
- F2
These shares are held directly by Vensana Capital I, L.P. ("Vensana I"). Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Each of the Reporting Person, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") is a managing director of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to share voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of the these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Remarks
This amended Form 4 amends and restates Table II of the Form 4 filed by the Reporting Person on February 10, 2026 (the "Prior Form 4") and is being filed to correct the number of shares reported in Column 5 of Table II of the Prior Form 4 to reflect the Issuer's preferred stock converted on a one-for-one basis into shares of the Issuer's Common Stock prior to the closing of the Issuer's initial public offering of its Common Stock.